Deoxycholic acid-modified polyethylenimine based nanocarriers for RAGE siRNA therapy in acute myocardial infarction

Archives of Pharmacal Research

Volumn 38, Issue 7, 2015, Pages 1317-1324

  Ku, Sook Hee ^a   Hong, Jueun ^b,c   Moon, Hyung Ho ^b   Jeong, Ji Hoon ^a,d   Mok, Hyejung ^e   Park, Sungha ^b   Choi, Donghoon ^b   Kim, Sun Hwa ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Yonsei University Health System   (South Korea)

^c Korea Testing and Research Institute   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e Konkuk University   (South Korea)

Author keywords

Combination therapy; Myocardial ischemia; RAGE siRNA; Soluble RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; DEOXYCHOLIC ACID; LIGAND; NANOCARRIER; POLYETHYLENEIMINE; SMALL INTERFERING RNA; AGER PROTEIN, RAT; CARDIOTONIC AGENT; DRUG CARRIER; NANOMATERIAL;

ACUTE HEART INFARCTION; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG EFFICACY; EXTRACELLULAR MATRIX; GENE DELETION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; HEART INFARCTION SIZE; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MALE; NONHUMAN; PROTEIN DOMAIN; RAT; REPERFUSION INJURY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG POTENTIATION; GENETICS; METABOLISM; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; CARDIOTONIC AGENTS; DEOXYCHOLIC ACID; DRUG CARRIERS; DRUG SYNERGISM; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NANOSTRUCTURES; POLYETHYLENEIMINE; RATS; RNA, SMALL INTERFERING;

EID: 84937735945     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-014-0527-x     Document Type: Article

References (22)

1. Abu-Amara, M., S.Y. Yang, N. Tapuria, B. Fuller, B. Davidson, and A. Seifalian. 2010. Liver ischemia/reperfusion injury: Processes in inflammatory networks - A review. Liver Transplantation 16: 1016-1032.
2. Aleshin, A., R. Ananthakrishnan, Q. Li, R. Rosario, Y. Lu, W. Qu, F. Song, S. Bakr, M. Szabolcs, V. D'agati, R. Liu, S. Homma, A.M. Schmidt, S.F. Yan, and R. Ramasamy. 2008. RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model. American Journal of Physiology Heart and Circulatory Physiology 294: H1823-H1832.
3. Andrassy, M., H.C. Volz, J.C. Igwe, B. Funke, S.N. Eichberger, Z. Kaya, S. Buss, F. Autschbach, S.T. Pleger, I.K. Lukic, F. Bea, S.E. Hardt, P.M. Humpert, M.E. Bianchi, H. Mairbäurl, P.P. Nawroth, A. Remppis, H.A. Katus, and A. Bierhaus. 2008. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117: 3216-3226.
4. Bucciarelli, L.G., R. Ananthakrishnan, Y.C. Hwang, M. Kaneko, F. Song, D.R. Sell, C. Strauch, V.M. Monnier, S.F. Yan, A.M. Schmidt, and R. Ramasamy. 2008. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes 57: 1941-1951.
5. Bucciarelli, L.G., M. Kaneko, R. Ananthakrishnan, E. Harja, L.K. Lee, Y.C. Hwang, S. Lerner, S. Bakr, Q. Li, Y. Lu, F. Song, W. Qu, T. Gomez, Y.S. Zou, S.F. Yan, A.M. Schmidt, and R. Ramasamy. 2006. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation 113: 1226-1234.
6. Chae, S.Y., H.J. Kim, M.S. Lee, Y.L. Jang, Y. Lee, S.H. Lee, K. Lee, S.H. Kim, H.T. Kim, S.C. Chi, T.G. Park, and J.H. Jeong. 2011. Energy-independent intracellular gene delivery mediated by polymeric biomimetics of cell-penetrating peptides. Macromolecular Bioscience 11: 1169-1174.
7. Godbey, W.T., K.K. Wu, and A.G. Mikos. 1999. Size matters: Molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle. Journal of Biomedical Materials Research 45: 268-275.
8. Hofmann, M.A., S. Drury, C. Fu, W. Qu, A. Taguchi, Y. Lu, C. Avila, N. Kambham, A. Bierhaus, P. Nawroth, M.F. Neurath, T. Slattery, D. Beach, J. Mcclary, M. Nagashima, J. Morser, D. Stern, and A.M. Schmidt. 1999. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for s100/calgranulin polypeptides. Cell 97: 889-901.
9. Kim, D., J. Hong, H.H. Moon, H.Y. Nam, H. Mok, J.H. Jeong, S.W. Kim, D. Choi, and S.H. Kim. 2013. Anti-apoptotic cardioprotective effects of SHP-1 gene silencing against ischemia-reperfusion injury: use of deoxycholic acid-modified low molecular weight polyethyleneimine as a cardiac siRNA-carrier. Journal of Controlled Release 168: 125-134.
10. Kim, H., S. Lim, H.-H. Moon, S. Kim, K.-C. Hwang, M. Lee, S. Kim, and D. Choi. 2010. Hypoxia-inducible vascular endothelial growth factor gene therapy using the oxygen-dependent degradation domain in myocardial ischemia. Pharmaceutical Research 27: 2075-2084.
11. Lee, D., K.H. Lee, H. Park, S.H. Kim, T. Jin, S. Cho, J.H. Chung, S. Lim, and S. Park. 2013. The effect of soluble RAGE on inhibition of angiotensin II-mediated atherosclerosis in apolipoprotein E deficient Mice. PLoS ONE 8: e69669.
12. Lu, Q.L., G. Bou-Gharios, and T.A. Partridge. 2003. Non-viral gene delivery in skeletal muscle: a protein factory. Gene Therapy 10: 131-142.
13. Meloche, J., A. Courchesne, M. Barrier, S. Carter, M. Bisserier, R. Paulin, J.F. Lauzon-Joset, S. Breuils-Bonnet, É. Tremblay, S. Biardel, C. Racine, C. Courture, P. Bonnet, S.M. Majka, Y. Deshaies, F. Picard, S. Provencher, and S. Bonnet. 2013. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology. Journal of the American Heart Association 2: e005157.
14. Muhammad, S., W. Barakat, S. Stoyanov, S. Murikinati, H. Yang, K.J. Tracey, M. Bendszus, G. Rossetti, P.P. Nawroth, A. Bierhaus, and M. Schwaninger. 2008. The HMGB1 receptor RAGE mediates ischemic brain damage. Journal of Neuroscience 28: 12023-12031.
15. Orlova, V.V., E.Y. Choi, C. Xie, E. Chavakis, A. Bierhaus, E. Ihanus, C.M. Ballantyne, C.G. Gahmberg, M.E. Bianchi, P.P. Nawroth, and T. Chavakis. 2007. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO Journal 26: 1129-1139.
16. Ramasamy, R., S.J. Vannucci, S.S.D. Yan, K. Herold, S.F. Yan, and A.M. Schmidt. 2005. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15: 16R-28R.
17. Ruponen, M., S. Rönkkö, P. Honkakoski, J. Pelkonen, M. Tammi, and A. Urtti. 2001. Extracellular glycosaminoglycans modify cellular trafficking of lipoplexes and polyplexes. Journal of Biological Chemistry 276: 33875-33880.
18. Santilli, F., N. Vazzana, L.G. Bucciarelli, and G. Davì. 2009. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Current Medicinal Chemistry 16: 940-952.
19. Xia, J.-R., N.-F. Liu, and N.-X. Zhu. 2008. Specific siRNA targeting the receptor for advanced glycation end products inhibits experimental hepatic fibrosis in rats. International Journal of Molecular Sciences 9: 638-661.
20. Xu, Y., F. Toure, W. Qu, L. Lin, F. Song, X. Shen, R. Rosario, J. Garcia, A.M. Schmidt, and S.-F. Yan. 2010. Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. Journal of Biological Chemistry 285: 23233-23240.
21. Yan, S.F., R. Ramasamy, and A.M. Schmidt. 2009. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Reviews in Molecular Medicine 11: e9.
22. Zeng, S., N. Feirt, M. Goldstein, J. Guarrera, N. Ippagunta, U. Ekong, H. Dun, Y. Lu, W. Qu, A.M. Schmidt, and J.C. Emond. 2004. Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology 39: 422-432.